+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors



W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors



Investigational new Drugs 2019:



The PI3K pathway is aberrantly activated in many cancers and plays a critical role in tumour cell proliferation and survival, making it a rational therapeutic target. In the present study, the effects and the underlying mechanism of a new PI3K inhibitor, W941, were investigated in non-small-cell lung cancer (NSCLC). The results of this study showed that W941 inhibited the growth of A549 and Hcc827 cells with IC50 values of 0.12 and 0.23 μM, respectively, and that W941 markedly inhibited the growth of A549 xenograft tumours in a nude mouse model without decreasing body weight. Western blotting assays showed that W941 inhibited the phosphorylation of downstream proteins in the PI3K pathway (AKT, mTOR, p70S6K and 4EBP1) in both A549 and Hcc827 cells. In addition, after W941 treatment, a dose-dependent increase in the ratio of the LC3-II/I ratio was observed. When cells were pre-treated with chloroquine or bafilomycin A1, W941 increased the LC3-II/I ratio, suggesting that W941 acted as an autophagy inducer. Moreover, autophagy blockers enhanced apoptosis after W941 treatment, indicating that W941-induced autophagy actually protected the cells against its cytotoxicity. Our findings suggest that the combination of a PI3K inhibitor with an autophagy inhibitor might be a novel option for NSCLC treatment.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 069602015

Download citation: RISBibTeXText

PMID: 31823159


Related references

Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines. Molecular Cancer 12(1): 88, 2013

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leukemia Research 36(7): 912-920, 2012

Novel curcumin analogue IHCH exhibits potent anti‑proliferative effects by inducing autophagy in A549 lung cancer cells. Molecular Medicine Reports 10(1): 441-446, 2014

FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells. Cancer Letters 304(2): 97-106, 2011

A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer. Anti-Cancer Drugs 30(9): 900-908, 2019

Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. International Journal of Cancer 144(5): 1170-1179, 2019

The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma. Journal of Cancer 9(6): 987-997, 2018

A Phase II Randomized Trial with Captopril in Patients Who Have Received Radiation Therapy +/- Chemotherapy for Stage IIIIIB Nonsmall Cell Lung Cancer and Stage I Central Nonsmall Cell Lung Cancer, or Limited-stage Smallcell Lung Cancer: RTOG 0123. International Journal of Radiation Oncology*biology*physics 75(3): S461-S462, 2009

GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer. Cancer Biology and Therapy 20(9): 1206-1212, 2019

Assessment of proliferative fraction by PCNA in stage I nonsmall cell lung cancer. Laboratory Investigation 68(1): 129A, 1993

Synergistic anti-proliferative and pro-apoptotic activities of 5F and cisplatin in human non-small cell lung cancer NCI-H23 cells. Oncology Letters 14(5): 5347-5353, 2017

Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. Human and Experimental Toxicology 36(7): 692-700, 2017

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clinical Lung Cancer 14(4): 322-332, 2013

Anti-lung cancer potential of pure esteric-glycoside condurangogenin A against nonsmall-cell lung cancer cells in vitro via p21/p53 mediated cell cycle modulation and DNA damage-induced apoptosis. Pharmacognosy Magazine 11(Suppl 1): S73, 2015

Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. International Journal of Molecular Medicine 31(6): 1449-1456, 2013